Amgen, AstraZeneca Highlight Brodalumab Data to be Presented at EADV
October 03, 2013 at 06:06 AM EDT
Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22nd
